Exelixis (EXEL) Other Working Capital Changes (2010 - 2026)
Exelixis (EXEL) recorded quarterly Other Working Capital Changes of -$58.7 million in Q2 2026, down 160.45% quarter-over-quarter from $97.0 million in Q1 2026, and down 188.65% on a YoY basis from $66.2 million in Q2 2025.
Exelixis (EXEL) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Exelixis' Other Working Capital Changes history runs 17 years deep, the most recent figure standing at -$58.7 million for Q2 2026.
- In Q2 2026, Other Working Capital Changes fell 188.65% year-over-year to -$58.7 million; the TTM figure through Apr 2026 stood at $95.4 million (up 330.95% YoY), while the FY2026 annual figure was $133.8 million, up 530.42% from the prior year.
- Other Working Capital Changes was -$58.7 million for Q2 2026 at Exelixis, down from $97.0 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $104.7 million in Q3 2025 to a low of -$94.1 million in Q1 2025.
- Historically, Other Working Capital Changes has averaged $6.0 million across 5 years, with a median of -$5.4 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes surged 1671.89% in 2022, then slumped 1393.04% in 2024.
- A 5-year view of Other Working Capital Changes shows it stood at -$6.9 million in 2022, then soared by 566.98% to $32.3 million in 2023, then soared by 199.89% to $96.7 million in 2024, then sank by 149.26% to -$47.6 million in 2025, then decreased by 23.09% to -$58.7 million in 2026.
- The last three Other Working Capital Changes figures came in at -$58.7 million (Q2 2026), $97.0 million (Q1 2026), and -$47.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -58.65 Mn |
| Apr 3, 2026 | -58.65 Mn |
| Jan 2, 2026 | 97.03 Mn |
| Jan 2, 2026 | 97.03 Mn |
| Oct 3, 2025 | -47.65 Mn |
| Oct 3, 2025 | -47.65 Mn |
| Jul 4, 2025 | 104.71 Mn |
| Jul 4, 2025 | 104.71 Mn |
| Apr 4, 2025 | -20.32 Mn |
| Apr 4, 2025 | -20.32 Mn |
| Jan 3, 2025 | -94.15 Mn |
| Jan 3, 2025 | -94.15 Mn |
| Sep 27, 2024 | 96.73 Mn |
| Sep 27, 2024 | 96.73 Mn |
| Jun 28, 2024 | -23.59 Mn |
| Jun 28, 2024 | -23.59 Mn |
| Mar 29, 2024 | -10.08 Mn |
| Mar 29, 2024 | -10.08 Mn |
| Dec 29, 2023 | 32.25 Mn |
| Dec 29, 2023 | 32.25 Mn |